- Home
- FGF vs FGEN Comparison
FGF vs FGEN Comparison
Compare FGF & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- FGEN
- Stock Information
- Founded
- FGF 2012
- FGEN 1993
- Country
- FGF United States
- FGEN United States
- Employees
- FGF N/A
- FGEN N/A
- Industry
- FGF Property-Casualty Insurers
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- FGEN Health Care
- Exchange
- FGF Nasdaq
- FGEN Nasdaq
- Market Cap
- FGF 29.0M
- FGEN 33.5M
- IPO Year
- FGF N/A
- FGEN 2014
- Fundamental
- Price
- FGF $17.94
- FGEN $0.30
- Analyst Decision
- FGF
- FGEN Strong Buy
- Analyst Count
- FGF 0
- FGEN 1
- Target Price
- FGF N/A
- FGEN $10.00
- AVG Volume (30 Days)
- FGF 9.9K
- FGEN 1.6M
- Earning Date
- FGF 05-19-2025
- FGEN 05-05-2025
- Dividend Yield
- FGF N/A
- FGEN N/A
- EPS Growth
- FGF N/A
- FGEN N/A
- EPS
- FGF N/A
- FGEN N/A
- Revenue
- FGF $17,348,000.00
- FGEN $29,621,000.00
- Revenue This Year
- FGF N/A
- FGEN $544.98
- Revenue Next Year
- FGF N/A
- FGEN $9.45
- P/E Ratio
- FGF N/A
- FGEN N/A
- Revenue Growth
- FGF N/A
- FGEN N/A
- 52 Week Low
- FGF $14.21
- FGEN $0.18
- 52 Week High
- FGF $38.40
- FGEN $2.33
- Technical
- Relative Strength Index (RSI)
- FGF 40.71
- FGEN 38.86
- Support Level
- FGF $17.85
- FGEN $0.30
- Resistance Level
- FGF $19.25
- FGEN $0.38
- Average True Range (ATR)
- FGF 0.55
- FGEN 0.05
- MACD
- FGF 0.05
- FGEN -0.00
- Stochastic Oscillator
- FGF 36.77
- FGEN 16.30
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segment includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.